10-Q Filing

REGENERON PHARMACEUTICALS, INC. CIK: 872589 Q1 2018

Filing Information

Form Type	10-Q
Accession Number	`0001532176-18-000020`
Period End Date	20180331
Filing Date	20180503
Fiscal Year	2018
Fiscal Period	Q1
XBRL Instance	regn-20180331.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 71 Income Statement 50 Cash Flow Statement 50

Balance Sheet 71 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$812.73M	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$811.77M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.02B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$596.85M	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$605.46M	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$1.53B	USD	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$1.54B	USD	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Accounts Receivable from Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$168.85M	USD	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Accounts Receivable from Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$193.68M	USD	Point-in-time
Accounts receivable from Bayer	`AccountsAndNotesReceivableNet`	$243.14M	USD	Point-in-time
Accounts receivable from Bayer	`AccountsAndNotesReceivableNet`	$242.01M	USD	Point-in-time
Inventories	`InventoryNet`	$726.14M	USD	Point-in-time
Inventories	`InventoryNet`	$820.40M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$155.45M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$224.97M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$4.34B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$4.54B	USD	Point-in-time
Treasury Stock, shares outstanding (in shares)	`TreasuryStockShares`	3.76M	shares	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$1.82B	USD	Point-in-time
Treasury Stock, shares outstanding (in shares)	`TreasuryStockShares`	3.76M	shares	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$1.49B	USD	Point-in-time
Property, Plant, and Equipment, Net	`PropertyPlantAndEquipmentNet`	$2.36B	USD	Point-in-time
Property, Plant, and Equipment, Net	`PropertyPlantAndEquipmentNet`	$2.39B	USD	Point-in-time
Deferred tax assets	`DeferredTaxAssetsLiabilitiesNetNoncurrent`	$532.27M	USD	Point-in-time
Deferred tax assets	`DeferredTaxAssetsLiabilitiesNetNoncurrent`	$506.29M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$78.98M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$77.87M	USD	Point-in-time
Total assets	`Assets`	$9.37B	USD	Point-in-time
Total assets	`Assets`	$8.76B	USD	Point-in-time
Accounts Payable	`AccountsPayableCurrentAndNoncurrent`	$178.18M	USD	Point-in-time
Accounts Payable	`AccountsPayableCurrentAndNoncurrent`	$207.61M	USD	Point-in-time
Accrued Liabilities and Other Liabilities	`AccruedLiabilitiesAndOtherLiabilities`	$637.16M	USD	Point-in-time
Accrued Liabilities and Other Liabilities	`AccruedLiabilitiesAndOtherLiabilities`	$666.22M	USD	Point-in-time
Deferred revenue from Sanofi, current portion	`DeferredRevenueFromRelatedPartyCurrent`	$177.75M	USD	Point-in-time
Deferred revenue from Sanofi, current portion	`DeferredRevenueFromRelatedPartyCurrent`	$231.45M	USD	Point-in-time
Deferred Revenue, Current	`DeferredRevenueCurrent`	$142.39M	USD	Point-in-time
Deferred Revenue, Current	`DeferredRevenueCurrent`	$160.47M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.14B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.27B	USD	Point-in-time
Capital and facility lease obligations	`Capitalandfacilityleaseobligationsnoncurrent`	$703.45M	USD	Point-in-time
Capital and facility lease obligations	`Capitalandfacilityleaseobligationsnoncurrent`	$704.64M	USD	Point-in-time
Deferred revenue from Sanofi	`DeferredRevenueFromRelatedPartyNoncurrent`	$379.94M	USD	Point-in-time
Deferred revenue from Sanofi	`DeferredRevenueFromRelatedPartyNoncurrent`	$406.78M	USD	Point-in-time
Deferred Revenue, Noncurrent	`DeferredRevenueNoncurrent`	$257.97M	USD	Point-in-time
Deferred Revenue, Noncurrent	`DeferredRevenueNoncurrent`	$249.26M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$152.07M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$169.92M	USD	Point-in-time
Total liabilities	`Liabilities`	$2.81B	USD	Point-in-time
Total liabilities	`Liabilities`	$2.62B	USD	Point-in-time
Preferred Stock	`PreferredStockValue`	-	USD	Point-in-time
Preferred Stock	`PreferredStockValue`	-	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$3.51B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$3.61B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$3.29B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$2.95B	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$640.00K	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-15.59M	USD	Point-in-time
Treasury stock	`TreasuryStockValue`	$316.24M	USD	Point-in-time
Treasury stock	`TreasuryStockValue`	$316.24M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$6.57B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$6.14B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$9.37B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$8.76B	USD	Point-in-time

Income Statement 50 line items

Line Item	Tag	Value	Unit	Period
Net product sales	`SalesRevenueGoodsNet`	$858.25M	USD	1 Quarter
Net product sales	`SalesRevenueGoodsNet`	$987.91M	USD	1 Quarter
Sanofi collaboration revenue	`RevenueFromRelatedParties`	$210.37M	USD	1 Quarter
Sanofi collaboration revenue	`RevenueFromRelatedParties`	$189.49M	USD	1 Quarter
Bayer Collaboration Revenue	`OtherCollaborationRevenue`	$193.94M	USD	1 Quarter
Bayer Collaboration Revenue	`OtherCollaborationRevenue`	$247.93M	USD	1 Quarter
Other revenue	`OtherSalesRevenueNet`	$86.16M	USD	1 Quarter
Other revenue	`OtherSalesRevenueNet`	$56.44M	USD	1 Quarter
Total revenues	`Revenues`	$1.51B	USD	1 Quarter
Total revenues	`Revenues`	$1.32B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$507.44M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$498.59M	USD	1 Quarter
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$296.85M	USD	1 Quarter
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$330.77M	USD	1 Quarter
Cost of goods sold	`CostOfGoodsSold`	$61.25M	USD	1 Quarter
Cost of goods sold	`CostOfGoodsSold`	$69.24M	USD	1 Quarter
Cost of collaboration and contract manufacturing	`Costofmanufacturing`	$22.91M	USD	1 Quarter
Cost of collaboration and contract manufacturing	`Costofmanufacturing`	$45.66M	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$944.25M	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$888.45M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$567.23M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$430.54M	USD	1 Quarter
Other income, net	`OtherNonoperatingIncomeExpense`	$9.25M	USD	1 Quarter
Other income, net	`OtherNonoperatingIncomeExpense`	$24.61M	USD	1 Quarter
Interest Expense	`InterestExpense`	$6.44M	USD	1 Quarter
Interest Expense	`InterestExpense`	$7.50M	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$1.75M	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$18.17M	USD	1 Quarter
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$432.29M	USD	1 Quarter
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$585.40M	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$183.36M	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$107.42M	USD	1 Quarter
Net income	`NetIncomeLoss`	$477.98M	USD	1 Quarter
Net income	`NetIncomeLoss`	$248.93M	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$4.44	USD	1 Quarter
Net income per share - basic	`EarningsPerShareBasic`	$2.36	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$4.16	USD	1 Quarter
Net income per share - diluted	`EarningsPerShareDiluted`	$2.16	USD	1 Quarter
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	105.57M	shares	1 Quarter
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	107.65M	shares	1 Quarter
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	114.91M	shares	1 Quarter
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	115.11M	shares	1 Quarter
Net income	`NetIncomeLoss`	$477.98M	USD	1 Quarter
Net income	`NetIncomeLoss`	$248.93M	USD	1 Quarter
Unrealized gain (loss) on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$6.96M	USD	1 Quarter
Unrealized gain (loss) on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-11.08M	USD	1 Quarter
Unrealized gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	-	USD	1 Quarter
Unrealized gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	$1.44M	USD	1 Quarter
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$468.34M	USD	1 Quarter
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$255.89M	USD	1 Quarter

Cash Flow Statement 50 line items

Line Item	Tag	Value	Unit	Period
Net income	`NetIncomeLoss`	$477.98M	USD	1 Quarter
Net income	`NetIncomeLoss`	$248.93M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$38.12M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$36.36M	USD	1 Quarter
Non-cash compensation expense	`ShareBasedCompensation`	$133.79M	USD	1 Quarter
Non-cash compensation expense	`ShareBasedCompensation`	$82.42M	USD	1 Quarter
Other non-cash charges and expenses, net	`OtherNoncashIncomeExpense`	$4.19M	USD	1 Quarter
Other non-cash charges and expenses, net	`OtherNoncashIncomeExpense`	$-3.96M	USD	1 Quarter
Deferred taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$6.37M	USD	1 Quarter
Deferred taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$40.99M	USD	1 Quarter
Decrease (increase) in Sanofi, Bayer, and trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-30.41M	USD	1 Quarter
Decrease (increase) in Sanofi, Bayer, and trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$137.93M	USD	1 Quarter
Increase in Inventories	`IncreaseDecreaseInInventories`	$88.76M	USD	1 Quarter
Increase in Inventories	`IncreaseDecreaseInInventories`	$69.74M	USD	1 Quarter
Decrease (increase) in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$20.32M	USD	1 Quarter
Decrease (increase) in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-68.84M	USD	1 Quarter
(Decrease) increase in deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$-54.60M	USD	1 Quarter
(Decrease) increase in deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$12.40M	USD	1 Quarter
Increase in accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$187.69M	USD	1 Quarter
Increase in accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$76.65M	USD	1 Quarter
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$106.97M	USD	1 Quarter
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$140.76M	USD	1 Quarter
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$355.90M	USD	1 Quarter
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$618.74M	USD	1 Quarter
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$208.69M	USD	1 Quarter
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$601.31M	USD	1 Quarter
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$119.01M	USD	1 Quarter
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$255.28M	USD	1 Quarter
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$79.38M	USD	1 Quarter
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$50.46M	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-140.14M	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-425.41M	USD	1 Quarter
Proceeds in connection with capital and facility lease obligations	`ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities`	-	USD	1 Quarter
Proceeds in connection with capital and facility lease obligations	`ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities`	$57.00M	USD	1 Quarter
Payments in connection with capital and facility lease obligations	`RepaymentsOfLongTermDebtAndCapitalSecurities`	-	USD	1 Quarter
Payments in connection with capital and facility lease obligations	`RepaymentsOfLongTermDebtAndCapitalSecurities`	$12.86M	USD	1 Quarter
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$16.67M	USD	1 Quarter
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$13.43M	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$13.43M	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$60.81M	USD	1 Quarter
Net increase in cash, cash equivalents, and restricted cash	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$276.57M	USD	1 Quarter
Net increase in cash, cash equivalents, and restricted cash	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$206.76M	USD	1 Quarter
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$824.27M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.03B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$825.23M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$547.70M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$824.27M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.03B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$825.23M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$547.70M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.